Abstract: The present invention relates to an aqueous pharmaceutical suspension composition comprising: from about 0.2% to 20% of a substantially water soluble pharmaceutical active, e.g. acetaminophen; a suspension stabilizing effective amount of xanthan gum and microcrystalline cellulose; an effective amount of taste masking compositions; and water, as well as a process for producing such aqueous pharmaceutical suspensions.

Abstract: The present invention relates to topical aromatic releasing compositions substantially free from petrolatum and containing one or more volatile aromatic compounds selected from the group consisting of menthol, camphor and eucalyptus oil and mixtures thereof. In further embodiments, these compositions contain one or more topical actives, and are also useful for providing relief from symptoms associated with respiratory disorders.

Abstract: A film-coated extended release oral dosage composition containing the nasal decongestant pseudoephedrine sulfate in a unique polymer matrix core and a film-coating on such core containing the non-sedating antihistamine, loratadine, and use of the said composition for treating patients showing the signs and symptoms associated with upper respiratory diseases and nasal congestion are disclosed.

Abstract: The present invention relates to an aqueous pharmaceutical suspension composition comprising: from about 0.2% to 20% of a substantially water soluble pharmaceutical active, e.g. acetaminophen; a suspension stabilizing effective amount of xanthan gum and microcrystalline cellulose; an effective amount of taste masking compositions; and water, as well as a process for producing such aqueous pharmaceutical suspensions.

Abstract: The present invention encompasses the novel method of using .+-.phenylpropanolamine to induce mucous secretion in the upper airways of persons afflicted with sinusitis or otitis media characterized by retention of thickened respiratory secretions. These methods comprise administering to such person a safe and effective amount of .+-.phenylpropanolamine. It also encompasses certain novel oral compositions consisting essentially of l(-)-norephedrine and a pharmaceutically-acceptable excipient base.

Abstract: The subject invention involves compositions and methods of using loperamide and related compounds for treatment of symptoms associated with respiratory diseases.

Abstract: An orally administrable sustained-release pharmaceutical tablet having at least two layers, which are directly compressible, is disclosed. The first layer, an immediate-release layer, contains an orally active analgesic and is readily susceptible to disintegration in the stomach. The second layer, a sustained-release layer which is directly compressed onto the first layer, comprises an orally active decongestant admixed with a major amount of a sustained-release agent so as to display increased resistance to disintegration and erosion in the gastro-intestinal tract relative to the first layer.

Abstract: The present invention pertains to an unpleasant taste masking composition which comprises a flavoring agent having a bitter taste or unpleasant off-note and a sufficient amount of a non-bitter intense sweetener to nullify the taste or off-note of the flavoring agent. The unpleasant taste masking composition may be used in ingestible products such as hard and soft confections, chewing gum compositions and the like. The present invention also pertains to a method for preparing the unpleasant taste masking compositions and the ingestible products in which they may be used.

Abstract: Disclosed is a hard confection containing Palatinit (hydrogenated isomaltulose) and a medicinally active ingredient. Such a formulation has been found to dissolve more slowly than similar formulations based on sugar rendering them suitable for dispensing the active ingredient over an extended period of time.

Abstract: An aqueous, flavored, topical, nasal decongestant composition containing an amount of oxymetazoline or a pharmaceutically acceptable salt thereof, e.g., oxymetazoline HCl sufficient to effect nasal decongestion and an amount of a fruity flavor e.g. cherry flavor, sufficient to mask the medicinal after-taste of the composition, together with an aqueous carrier.

Abstract: A decongestant is disclosed consisting essentially of active components of from about 2 g to about 10 g of vegetable oil, from about 0.1 g to about 5 g of aloe vera, from about 3 mg to about 150 mg of zinc, from about 10 mg to about 1000 mg of vitamin C, from about 2,000 USP Units to about 70,000 USP Units of vitamin A, from about 20 IU to about 500 IU of vitamin E, from about 10 mg to about 300 mg of vitamin B-6, from about 50 mcg to about 2000 mcg of biotin, and from about 0.3 g to about 2 g of fruit pectin, per about 1 liter of the decongestant. The balance is carriers and solvents. The zinc is supplied as one or more therapeutic compounds of zinc.

Abstract: Disclosed is a method for the treatment of allergic rhinitis that manifests itself as rhinorrhea, nasal itching, sneezing, congestion and postnasal drip. The method comprises the administration from a nasal aerosol dispenser an effective amount of micronized triamcinolone acetonide suspended in dichlorodifluoromethane into the nasal cavity of a patient suffering from allergic rhinitis.

Abstract: A cough drop is provided comprising a hard candy outer shell and a powdered centerfill containing a rapidly-dissolving powder such as dextrose monohydrate and an active ingredient such as menthol and eucalyptus which is preferably in the form of a liquid blend and a spray-dried powder. The hard candy outer shell also contains menthol and eucalyptus as a liquid blend.When the outer shell is dissolved in the mouth or the centerfill is bitten into, the rapidly-dissolving powder acts to enhance the active-ingredient's activity in the mouth so that a discernible vaporization of active-ingredient is felt.

Abstract: A medicament adsorbate of decongestants and process for making same. The medicament adsorbate comprises a complex magnesium aluminum silicate having sorbed therein a decongestant. The complex magnesium aluminum silicate has the following typical chemical analysis:______________________________________ Ratio to Percent by Weight Aluminum Oxide ______________________________________ Silicon dioxide 56 to 59 14.0 to 29.5 Magnesium oxide 21 to 24 5.2 to 12.0 Aluminum oxide 2.0 to 4.0 1 Ferric oxide 0.4 to 0.6 Calcium oxide 1.1 to 1.5 Sodium oxide 2.5 to 3.5 Potassium oxide 0.5 to 1.0 Ignition Loss 5.5 to 12.

Abstract: The present invention provides certain novel substituted naphthalenes, indoles, benzofurans, and benzothiophenes of Formula I which are useful as inhibitors of leukotriene biosynthesis and as inhibitors of lipoxygenase. They are thus employed wherever it is medically necessary or desirable to inhibit these systems.

Abstract: A medicament adsorbate containing a magnesium trisilicate having a surface area of at least 400 m.sup.2 /g and having a flake-like structure with multiple interstitial spaces, and having adsorbed therein from about 1% to about 20% by weight of the adsorbate of a medicament drug, wherein the medicament drug is a decongestant.

Abstract: Eucalyptol is used to enhance skin permeation of bio-affecting agents.